BioSpace News Archive

POXEL S.A. announced that it will report its financial results for the full year 2019 on Thursday, March 26, 2020.

Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) being developed to treat infected, high-risk individuals with COVID-19

A Recent Report published by MarketResearch.biz, with the title “Global Gene Therapy Market Comprehensive Research and Forecast 2020-2029”, provides detailed information on the market in a confident manner.

Cinclus Pharma Holding AB announced that the company has successfully completed a financing round of SEK 250 million to fund the further clinical development of X842 – a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, reported financial results for the three months and full year ended December 31, 2019, and provided an update on its corporate activities and product pipeline.

Presentation based on positive Phase 3 pivotal study results of Sofpironium Bromide in Japanese Patients with Primary Axillary Hyperhidrosis

ReGelTec, Inc., a medical device company focused on the development and commercialization of spinal implants for chronic back pain, announced that it has received a patent from the United States Patent Office covering HYDRAFIL™, a hydrogel injected into the nucleus of a person’s intervertebral disc via a 17 gauge needle.

President of American Board of Clinical Lipidology and nationally recognized expert in cardiovascular disease prevention and the diagnosis and treatment of cholesterol and hypertensive disorders

The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, announced that management is scheduled to attend the 32nd Annual ROTH Conference on March 16th and 17th at The Ritz-Carlton in Orange County, California.

IGM Biosciences, Inc. announced that members of the management team will present at two upcoming investor conferences